Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Company Overview - Acadia Pharmaceuticals has seen a share price increase of approximately 26.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Acadia have trended downward, with the consensus estimate shifting down by 20% [2] - The overall direction of estimate revisions indicates a downward shift in expectations for the stock [4] VGM Scores - Acadia has an average Growth Score of C, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The aggregate VGM Score for Acadia is D, which is significant for investors not focused on a single strategy [3] Market Outlook - Acadia holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Performance - Acadia is part of the Zacks Medical - Biomedical and Genetics industry, where Blueprint Medicines has gained 29.5% over the past month [5] - Blueprint Medicines reported revenues of $149.41 million for the last quarter, reflecting a year-over-year increase of 55.4% [5] - The expected loss for Blueprint Medicines in the current quarter is $0.54 per share, which represents a year-over-year improvement of 32.5% [6]